EAST WINDSOR, N.J.--(BUSINESS WIRE)--NexMed, Inc. (Nasdaq: NEXM), a developer of innovative transdermal products based on the NexACT® drug delivery technology, today announced that Health Canada has confirmed Good Manufacturing Practices (GMP) compliant status for its manufacturing facility in East Windsor, NJ. NexMed’s New Drug Submission for its topical erectile dysfunction treatment was accepted by Health Canada for review on February 15, 2008.
